CoChat

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

Open access
Ossenkoppele, Rik, Reimand, Juhan, Smith, Ruben, Leuzy, Antoine, Strandberg, Olof, Palmqvist, Sebastian, Stomrud, Erik, Zetterberg, Henrik, the Alzheimer's Disease Neuroimaging Initiative, Scheltens, Philip, Dage, Jeffrey L, Bouwman, Femke, Blennow, Kaj, Mattsson‐Carlgren, Niklas, Janelidze, Shorena, Hansson, Oskar · 2021 · EMBO Molecular Medicine
Cited by 130

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer’s disease (AD) related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n=400) and ADNI (n=371). All had tau-PET ([ 18 F]RO948 in BioFINDER-2, [ 18 F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66% and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau PET associated with higher age, and APOE ε4-carriership and Aβ-positivity, while increased tau-PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p-tau181 and p-tau217 levels being more tightly linked with early markers of AD (especially Aβ pathology), while tau-PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202114398

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 130

Metadata

Authors
Ossenkoppele, R., Reimand, J., Smith, R., Leuzy, A., Strandberg, O., Palmqvist, S., Stomrud, E., Zetterberg, H., Initiative, T. A. D. N., Scheltens, P., Dage, J. L., Bouwman, F., Blennow, K., Mattsson‐Carlgren, N., Janelidze, S., & Hansson, O.
Venue
EMBO Molecular Medicine
Published
2021-07-13
Volume
13
Issue
8
Pages
e14398-e14398
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3178454960
Cited by
130
References
48
FWCI
13.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers. https://app.cochat.ai/papers/10.15252/emmm.202114398
The paper
Ossenkoppele, R., Reimand, J., Smith, R., Leuzy, A., Strandberg, O., Palmqvist, S., Stomrud, E., Zetterberg, H., Initiative, T. A. D. N., Scheltens, P., Dage, J. L., Bouwman, F., Blennow, K., Mattsson‐Carlgren, N., Janelidze, S., & Hansson, O. (2021). Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202114398

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.